

# 1 KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney

2

3 Yutaro Mori<sup>1, \*</sup>, Corby Fink<sup>2</sup>, Takaharu Ichimura<sup>1</sup>, Keisuke Sako<sup>1</sup>, Makiko Mori<sup>1</sup>, Nathan N. Lee<sup>1</sup>, Philipp  
4 Aschauer<sup>3</sup>, Krishna M. Padmanabha Das<sup>3</sup>, SoonGweon Hong<sup>1,4</sup>, Minsun Song<sup>1,4</sup>, Robert F. Padera Jr.<sup>5</sup>,  
5 Astrid Weins<sup>5</sup>, Luke P. Lee<sup>1,4</sup>, Mahmoud L. Nasr<sup>1,4</sup>, Gregory A. Dekaban<sup>2,6</sup>, Jimmy D. Dikeakos<sup>2</sup> and Joseph  
6 V. Bonventre<sup>1,4, \*</sup>

7 1Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

8 2Department of Microbiology & Immunology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada

9 3Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA

10 4Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115,  
11 USA

12 5Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

13 6Molecular Medicine Research Group, Robarts Research Institute, Western University, London, ON, Canada

14

15 \* Corresponding authors:

16

## 17 Abstract

18 SARS-CoV-2 precipitates respiratory distress by infection of airway epithelial cells and is often  
19 accompanied by acute kidney injury. We report that Kidney Injury Molecule-1/T cell immunoglobulin mucin  
20 domain 1 (KIM-1/TIM-1) is expressed in lung and kidney epithelial cells in COVID-19 patients and is a  
21 receptor for SARS-CoV-2. Human and mouse lung and kidney epithelial cells express KIM-1 and  
22 endocytose nanoparticles displaying the SARS-CoV-2 spike protein (virosomes). Uptake was inhibited by  
23 anti-KIM-1 antibodies and TW-37, a newly discovered inhibitor of KIM-1-mediated endocytosis. Enhanced  
24 KIM-1 expression by human kidney tubuloids increased uptake of virosomes. KIM-1 binds to the SARS-  
25 CoV-2 Spike protein *in vitro*. KIM-1 expressing cells, not expressing angiotensin-converting enzyme 2  
26 (ACE2), are permissive to SARS-CoV-2 infection . Thus, KIM-1 is an alternative receptor to ACE2 for  
27 SARS-CoV-2. KIM-1 targeted therapeutics may prevent and/or treat COVID-19.

28

## 29 Keywords

1 Kidney organoids, virosomes, spike protein, acute kidney injury

2

3 **\*Yutaro Mori, MD, PhD**

4 Research Fellow in Medicine

5 Division of Renal Medicine, Department of Medicine,

6 Brigham and Women's Hospital, Harvard Medical School

7 Phone : (617)-525-3037

8 Email : [y-mori.kid@tmd.ac.jp](mailto:y-mori.kid@tmd.ac.jp)

9

10 **\*Joseph V. Bonventre, MD, PhD**

11 Samuel A. Levine Distinguished Professor of Medicine, Harvard Medical School

12 Constantine L. Hampers, MD Distinguished Chair in Renal Medicine

13 Chief, Division of Renal Medicine

14 Chief, Division of Engineering in Medicine

15 Department of Medicine, Brigham and Women's Hospital

16 4 Blackfan Circle Room 576, Boston, MA 02115

17 Phone : (617) 525-5966, Fax : (617) 525-5965

18 Email : [joseph\\_bonventre@hms.harvard.edu](mailto:joseph_bonventre@hms.harvard.edu)

19

## 1 Introduction

2 Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 <sup>1</sup> was first reported at Wuhan in China in  
3 2019 <sup>2</sup>. The disease has since reached pandemic proportions <sup>3,4</sup>. SARS-CoV-2-related respiratory failure  
4 and acute kidney injury (AKI) are significant complications of infection <sup>5-7</sup> and are associated with high  
5 morbidity and mortality <sup>8,9</sup>. **Kidney Injury Molecule-1 (KIM-1)**, also identified as Hepatitis A Virus Cellular  
6 Receptor 1 (HAVCR1) in hepatocytes <sup>10</sup>, and T-cell immunoglobulin and mucin domain 1 (TIM-1), was  
7 identified by our group as the most upregulated protein in the kidney proximal tubule after a wide variety  
8 of injurious influences including ischemia, nephrotoxicants, sepsis, and immune-related injury and its  
9 cleaved ectodomain is often used as a blood and urine marker for kidney injury <sup>11-16</sup>. KIM-1 has been  
10 reported as a receptor for Ebola virus <sup>17</sup> and Dengue virus <sup>18</sup>. KIM-1 also facilitates cellular uptake of West  
11 Nile virus <sup>19</sup>. KIM-1 can mediate internalization and transduction of Marburg virus glycoprotein (GP) and  
12 full-length Ebola virus GP pseudovirions into human mucosal epithelia from the trachea <sup>17</sup>. KIM-1-mediated  
13 infection was efficiently inhibited by anti-human KIM-1 IgV domain-specific monoclonal antibody ARD5 <sup>20</sup>.  
14 In the kidney, KIM-1 acts as a receptor for phosphatidylserine exposed on the surface of apoptotic cells  
15 and for oxidized lipids <sup>21</sup>. Once ligands bind to KIM-1, they are internalized by phagocytosis or endocytosis.  
16 We have recently identified TW-37 as an inhibitor of KIM-1-mediated oxidized lipid and palmitic acid (bound  
17 to albumin) uptake <sup>22</sup>.

18 The SARS-CoV-2 envelope contains a spike (S) glycoprotein, consisting of S1 and S2 subunits  
19 <sup>23</sup>. After infection, the trimeric S protein is cleaved into the two subunits, and S1, which contains the  
20 receptor-binding domain, binds to angiotensin-converting enzyme 2 (ACE2) and is internalized by lung  
21 epithelium. In addition to ACE2, carcinoembryonic antigen-related cell adhesion molecule (CEACAM) is  
22 known to be a receptor for SARS-CoV <sup>24</sup>. KIM-1 has an N-terminus conserved IgV domain with high  
23 homology with CEACAM's IgV domain to which the S1 subunit binds <sup>25</sup>. T-cell immunoglobulin and mucin  
24 domain 3 (TIM-3), another KIM/TIM-family member protein, forms a heterodimer with CEACAM <sup>26</sup>.  
25 Although KIM-1 is expressed at much higher levels in the kidney, it has also been reported to be expressed  
26 in human primary airway epithelial cells in pulmonary disease, human non-small-cell lung cancer, and  
27 human lung adenocarcinoma A549 cells <sup>27,28</sup>. KIM-1 is also expressed in Vero E6 monkey kidney cells

1 used for *in vitro* expansion and maintenance of Coronaviruses, including SARS-CoV-2 and other viruses  
2 <sup>29</sup>.

3 Here, we show that KIM-1 acts as a receptor for SARS-CoV-2 both in lung and kidney epithelia.  
4 KIM-1 expression in alveolar epithelium co-localizes in cells with SARS-CoV-2 nucleocapsid protein in  
5 post-mortem lung samples from COVID-19 patients. KIM-1 can bind to and mediate the internalization of  
6 liposomal nanoparticles displaying the SARS-CoV-2 spike protein ectodomain on their surface (virosomes)  
7 *in vitro*. The internalization of virosomes is inhibited both by anti-KIM-1 antibodies and TW-37. Molecular  
8 binding between KIM-1 and SARS-CoV-2 Spike protein was detected. KIM-1 expressing cells that did not  
9 express angiotensin-converting enzyme 2 (ACE2) were infected by SARS-CoV-2. Thus, KIM-1 may play  
10 an essential role in viral infection and can be a potential therapeutic target to mitigate the effects of SARS-  
11 CoV-2 in both lung and kidney.

12

## 1 RESULTS

### 2 **KIM-1 is expressed in COVID-19 patient autopsy lung samples.**

3 KIM-1 was expressed in the post-mortem lungs of 10 of 11 patients who died following SARS-CoV-2  
4 infection. KIM-1 was present in pan-cytokeratin-positive alveolar epithelial cells that were dislodged and  
5 formed debris-like clusters in most cases. In two patients (Patient 1 and 2), positive staining for SARS-  
6 CoV-2 nucleocapsid protein was present in KIM-1-positive and pan-cytokeratin-positive alveolar epithelial  
7 cells (**Fig. 1a**). KIM-1 (detected with two antibodies (AF1750 and AKG7)) was also co-localized with  
8 surfactant protein C (**Fig. 1a**). KIM-1 was detected using two different antibodies (AF1750 polyclonal and  
9 AKG7 monoclonal<sup>20</sup>). ACE2, a well-known receptor for SARS-CoV-2, was expressed and, in patient 1, is  
10 seen co-localized with KIM-1 and pan-cytokeratin (**Fig. 1a**). KIM-1 expression was very weak in non-  
11 COVID-19 patient lung autopsy samples (**Supplementary Fig. 1**).

12

### 13 **KIM-1 is expressed in COVID-19 patient biopsy and autopsy kidney proximal tubules.**

14 Since AKI is a frequent manifestation of COVID-19, we evaluated KIM-1 expression in COVID-19 patient  
15 kidney biopsies from 3 live patients with AKI who survived their hospitalization and 30 post-mortem kidney  
16 samples from patients with documented SARS-CoV-2 infection during their terminal hospitalization. KIM-  
17 1 expression was seen in all 3 biopsy cases, with approximately 10% of proximal tubules staining positive  
18 in both the cortex and outer medulla (**Fig. 1b and 1c**). Estimated glomerular filtration rate (GFR) and brief  
19 descriptions of the predominant renal pathology at the time of biopsy are presented in **Fig. 1c**. KIM-1  
20 positive tubules were dilated with some tubules containing cellular debris. ACE2 is widely expressed on  
21 the apical side of proximal tubules in the same regions as KIM-1. KIM-1 positive tubules tended to have  
22 reduced ACE2 staining, suggesting that ACE2 might be down-regulated as tubules dedifferentiate and  
23 enhance KIM-1 expression in **Fig. 1b**. We detected KIM-1 in 14 of 30 autopsy cases (**Fig. 1d**). In some  
24 patients, KIM-1 was expressed in relatively well-preserved tubules; however, in most kidneys with KIM-1  
25 expression, the protein was localized in exfoliated tubular cells due to postmortem artifacts. In some cases,  
26 ACE2 was also detected in those exfoliated cells. Thus, in COVID-19 patient kidneys, KIM-1 was frequently  
27 expressed, and significant tubular injury and KIM-1 expression were associated with less ACE2 expression

1 in the proximal tubules. We compared this reciprocal response between KIM-1 and ACE2 to a well-  
2 established mouse model of AKI. When KIM-1 and ACE2 were stained in post-ischemia-reperfusion injury  
3 (IRI) in mouse kidneys, ACE2 was down-regulated when KIM-1 was increased in flattened epithelial cells  
4 of the proximal tubules (**Fig. 1e**). In one of the autopsy kidneys from a male in his fifties with an eGFR of  
5 16 ml/min/1.73m<sup>2</sup>, SARS-CoV-2 nucleocapsid protein was observed in focal areas of proximal tubules and  
6 intraluminal casts of cellular debris (**Fig. 1f, g**).

7

### 8 **The role of KIM-1 in promoting SARS-CoV-2 entry in lung alveolar epithelial cells.**

9 SARS-CoV-2 virosomes were constructed of phospholipid liposomes conjugated to His-tagged spike  
10 ectodomain on their surfaces (**Fig. 2a**), and uptake of these fluorescently (Dil) labeled biomimetic viruses  
11 (virosomes, **Fig. 2a**) was assessed *in vitro* after confirming virosomes and control empty liposomes were  
12 equally labeled by Dil (**Supplementary Fig. 2**). Virosomes do not contain phosphatidylserine or  
13 phosphatidylethanolamine that are established ligands for KIM-1<sup>21</sup>. A549 cells, adenocarcinoma human  
14 alveolar basal epithelial cells, express KIM-1 and endocytosed SARS-CoV-2 virosomes while there was  
15 minimal uptake of unconjugated labelled liposomes (**Fig. 2b**) as assessed by confocal microscopy and  
16 quantified by flow cytometry. Cellular uptake of virosomes was efficiently inhibited by treatment with anti-  
17 KIM-1 IgG or with TW-37, our newly discovered inhibitor for KIM-1-mediated endocytosis<sup>22</sup> (**Fig. 2c**).  
18 Virosomes were taken up by 92.3% ± 1.1% of A549 cells, and anti-KIM-1 antibodies and TW-37 decreased  
19 the uptake to 44.9% ± 17.0% and 3.5% ± 0.2%, respectively quantitated by flow cytometry (**Fig. 2d**). ACE2  
20 was also expressed in A549 cells and was not altered in expression by anti-KIM-1 antibody (**Fig. 2e**). We  
21 also analyzed the uptake of virosomes by mouse primary lung epithelial cells. Cells were isolated from  
22 wild-type mice and mice carrying a mutation in the KIM-1 mucin domain (KIM-1<sup>Δmucin</sup> mice)<sup>30</sup>. KIM-1<sup>Δmucin</sup>  
23 serves as a functional knockout with reduced epithelial cell uptake of known KIM-1 ligands<sup>16,31</sup>. Wild-type  
24 mouse primary lung epithelial cells took virosomes up efficiently, similar to A549 cells. Treatment with anti-  
25 KIM-1 antibody or TW-37 (10 μM) dramatically decreased the uptake of virosomes, and KIM-1<sup>Δmucin</sup> cells  
26 showed significantly less uptake than wild-type cells (**Fig. 2f, g**).

27 To study further the KIM-1-mediated SARS-CoV-2 entry into lung epithelial cells, we developed a

1 3D model of human alveoli (“alveoloids”) using A549 cells (**Fig. 2h**). Fluorescently-labeled SARS-CoV-2  
2 spike protein conjugated virosomes were taken up by alveoloids, and this uptake was inhibited by TW-37  
3 (10  $\mu$ M) treatment (**Fig. 2h**).

4

#### 5 **The role of KIM-1 in the promotion of SARS-CoV-2 entry into kidney cells.**

6 A stably transfected LLC-PK1 pig kidney cell line expressing human KIM-1 (hKIM-1-LLC-PK1), and a  
7 control line without KIM-1 expression (pcDNA3-LLC-PK1), were incubated with fluorescently-labeled  
8 SARS-CoV-2 spike protein conjugated virosomes (**Fig. 3a**). The hKIM-1-LLC-PK1 cells endocytosed  
9 SARS-CoV-2 virosomes in a KIM-1-dependent manner, whereas there was no uptake of unconjugated  
10 empty liposomes (**Fig. 3a**) as assessed by confocal microscopy. TW-37 (10  $\mu$ M) pre-treatment for 30 min  
11 markedly reduced uptake of SARS-CoV-2 virosomes into hKIM-1-LLC-PK1 cells (**Fig. 3b**). To confirm  
12 virosome internalization in addition to cell surface attachment, we analyzed Z-stack confocal images of  
13 Dil-labeled virosome uptake by LLC-PK1 cells expressing human KIM-1 treated with or without TW-37 (**Fig.**  
14 **3c**). TW-37 treatment decreased this internalization. Additionally, we tested virosome uptake by LLC-PK1  
15 cells in a microfluidic channel with shear stress recapitulating the flow of formative urine. LLC-PK1 cells  
16 took up SARS-CoV-2 virosomes in a KIM-1-dependent manner as well, which was dramatically inhibited  
17 by TW-37 (**Fig. 3d**). Furthermore, we tested attachment and entry of GFP-labeled coronavirus-based  
18 SARS-CoV-2 pseudovirus (CoV2-01, SARS-CoV-2-S(GFP)) having SARS-CoV-2 Spike on their surface  
19 on LLC-PK1 cells stably expressing KIM-1 or control pcDNA in a co-cultured condition. Infection of this  
20 pseudovirus visualized by GFP was dominantly observed in hKIM-1-LLC-PK1 cells but not in pcDNA-LLC-  
21 PK1 cells (**Fig. 3e**). Additionally, soluble KIM-1 cleaved from hKIM-1-LLC-PK1 cells does not enhance  
22 infection on pcDNA-LLC-PK1 cells (**Fig. 3e**).

23 Both hKIM-1-LLC-PK1 and pcDNA3-LLC-PK1 cells stained positively for ACE2; however, much  
24 of the ACE2 was intracellular. pcDNA3-LLC-PK1 control cells appeared to have more intense and defuse  
25 ACE2 staining, even though the cells did not demonstrate significant uptake of the virosomes compared  
26 to the hKIM-1-LLC-PK1 cells (**Fig. 3f**). ACE2 protein expression was confirmed by western blot analysis  
27 of the cell lysates from both cell lines, whereas KIM-1 was expressed only in the hKIM-1-LLC-PK1 cells

1 (Fig. 3g). ACE2 bands are located at approximately 75 kDa and 120 kDa<sup>32</sup>. ACE2 and KIM-1 were co-  
2 stained and analyzed in high magnification confocal microscope images, ACE2 was localized to the  
3 cytoplasm with small amounts on the cell surface, while KIM-1 expression was primarily on the cell surface  
4 (arrows) (Fig. 3h). We tested uptake by LLC-PK1 cells expressing KIM-1 mutants of the binding motif, a  
5 four-amino acid motif (Tryptophan-Phenylalanine-Asparagine-Aspartic acid, WFND, amino acid residues  
6 112-115) in its extracellular Ig domain that serves to mediate phosphatidylserine (PS) binding to verify the  
7 KIM-1's motifs important for uptake of Spike. Cells expressed mouse KIM-1 with Alanine-Alanine (AA)  
8 replacing either WF or ND<sup>16</sup>. Virosome uptake by the WFAA mutant KIM-1-expressing cells was similar to  
9 wild-type KIM-1 (WFND) expressing cells (Fig. 3i). By contrast, there was significantly less virosome  
10 uptake by AAND expressing cells. Thus the WF motif is necessary for uptake of Spike. This is different  
11 from the binding of KIM-1 to phosphatidylserine on apoptotic cells where modification of either the WF or  
12 ND amino acids eliminates binding<sup>16</sup>.

13

#### 14 **Three-dimensional human renal epithelial tubuloids take up virosomes.**

15 We have developed a method to generate epithelial KIM-1 expressing "tubuloids" from kidney tissue  
16 derived from human subjects<sup>22</sup>. Human primary epithelial cell cultures were established from the non-  
17 tumor kidney tissue removed from patients with kidney cancer. Those primary cells were cultured in  
18 suspension with growth factors and Matrigel in non-adherent dishes (see Methods). KIM-1 expressing cells  
19 of human tubuloids took up Dil-labeled virosomes, but not Dil-labeled empty liposomes (Fig. 4a). With the  
20 uptake of spike conjugated virosomes, the tubuloids maintained their tubule-like three-dimensional  
21 structures as seen in phase-contrast images (Fig. 4b). Since well-developed tubuloids with polar  
22 epithelium reduce expression of KIM-1, likely due to progressive differentiation of the tubular epithelium,  
23 we enhanced human KIM-1 expression by infecting tubuloids with an adenovirus expressing KIM-1  
24 (Adenovirus-KIM-1) or the control vector expressing  $\beta$ -galactosidase ( $\beta$ -GAL) (Adenovirus- $\beta$ -GAL). Both  
25 viral vectors contained a GFP expression cDNA for tracing viral infection and transgene expression in the  
26 infected cells. After 48 hours of infection, we added Dil-labeled virosomes to the tubuloids (Fig. 4c).  
27 Adenovirus-KIM-1 infected GFP-positive tubuloid cells showed high uptake of virosomes (Fig. 4c, left) and



1 robust expression of KIM-1 protein (**Fig. 4c**, right). The KIM-1 infected tubuloids showed polarized  
2 expression of KIM-1 similar to proximal tubules *in vivo* and expressed ACE2 (**Fig. 4d**). In contrast to the  
3 Adenovirus-KIM-1 infected cells, control Adenovirus- $\beta$ -GAL infected tubuloids showed little KIM-1 staining  
4 and little uptake of virosomes or oxidized LDL (data not shown). The uptake of virosomes by the tubuloids  
5 overexpressing KIM-1 was dose-dependent (**Fig. 4e**). Quantification of ACE2 expression by flow cytometry  
6 on tubuloids infected by Adenovirus-KIM-1 or control Adenovirus- $\beta$ -GAL, after digestion into single cells,  
7 revealed a mean 29.8% decrease on single-cell ACE2 expression secondary to Adenovirus-KIM-1  
8 infection (**Fig. 4f**). Adenovirus-KIM-1 infection decreased Lotus tetragonolobus lectin (LTL) expression  
9 when compared with control Adenovirus- $\beta$ -GAL treatment, indicating that KIM-1 expression induces de-  
10 differentiation of human tubule epithelial cells in tubuloids (**Supplementary Fig. 3**). To demonstrate the  
11 effect of KIM-1 on virosome uptake also in human kidney organoids, we treated organoids, derived from  
12 H9 embryonic stem cells, with 5  $\mu$  M cisplatin for 48 hours to induce KIM-1 expression. The control and  
13 cisplatin-treated organoids were then exposed to Dil-labeled virosomes for 3 hours. Cisplatin treatment  
14 induced KIM-1 expression and KIM-1-expressing cells took up much more virosomes when compared with  
15 control organoids not exposed to cisplatin (**Fig. 4g**).

#### 16 17 **KIM-1 binds to SARS-CoV-2 Spike protein *in vitro*.**

18 KIM-1 binding to SARS-CoV-2 spike protein was tested by a flow cytometry-based binding assay. KIM-1-  
19 human Fc fusion protein was added to biotin-tagged SARS-CoV-2 Spike protein-bound avidin-beads to  
20 evaluate binding of KIM-1 to Spike. Bound KIM-1 was detected by flow cytometry after applying FITC-  
21 conjugated anti-human Fc antibody (**Fig. 5a and 5b**). This binding was inhibited to background levels  
22 following TW-37 addition.

#### 23 24 **KIM-1 is a receptor for SARS-CoV-2.**

25 To demonstrate if KIM-1 acts as a receptor for live SARS-CoV-2, we tested whether KIM-1 enhances  
26 SARS-CoV-2 infection and replication by an *in vitro* microneutralization assay for SARS-CoV-2<sup>33</sup>. We used  
27 293 cells expressing KIM-1 but not ACE2, 293T cells expressing ACE2 without KIM-1 and 293 cells

1 expressing control pcDNA plasmid. KIM-1-mediated virus replication was significantly higher than the low  
2 level of replication observed with control pcDNA expressing cells and approached the level of virus  
3 replication observed with ACE2 (**Fig. 5c**). Thus, KIM-1 acts as a receptor for SARS-CoV-2 virus *in vitro*.  
4

## 1 DISCUSSION

2 We have found that KIM-1 serves as a receptor for full length replication-competent SARS-CoV-2, SARS-  
3 CoV-2 spike protein expressing pseudovirus and virosomes, and that virosome uptake and pseudovirus  
4 infection are inhibited by anti-KIM-1 antibodies or TW-37, an inhibitor for KIM-1-mediated endocytosis <sup>22</sup>.  
5 Inhibition of this KIM-1-mediated uptake may be therapeutically useful in SARS-CoV-2 infection. KIM-1  
6 protein is detectable in partially autolyzed autopsy samples due to the protein's stability <sup>34</sup>. KIM-1-  
7 expressing proximal tubules have reduced expression of ACE2, a receptor for SARS-CoV-2 <sup>35</sup>, suggesting  
8 that KIM-1 may alter ACE2-mediated viral entry into cells.

9 Others have reported that they could not detect SARS-CoV-2 in kidneys <sup>36,37</sup>. We find SARS-CoV-  
10 2 nucleocapsid protein in albeit in a small subset of proximal tubules. KIM-1 expression, however, is  
11 commonly seen in the lungs of the SARS-CoV-2-infected patients. At present, there is controversy with  
12 respect to the presence of SARS-CoV-2 nuclear capsid protein immunoreactivity in kidney tissue of  
13 subjects with documented infection with some investigators reporting its presence <sup>38-41</sup>. In one study,  
14 SARS-CoV-2 RNA was reported in 38 of 63 post-mortem kidneys of patients who had SARS-CoV-2  
15 respiratory infection <sup>41</sup>. Others did not find evidence for virus in autopsy specimens <sup>36,42</sup>. We found clear  
16 evidence for viral infection in one patient but the infection was quite focal and could easily have been  
17 missed in a biopsy sample. It is possible there is early infection of the kidney but then the virus is cleared  
18 by the time the kidney specimen is obtained either later in the course of illness in the patient who develops  
19 AKI or when the patient succumbs to COVID-19. This viral clearance has also been reported to occur in  
20 the lung <sup>43</sup>.

21 Jemielity et al. reported that KIM-1 likely works as an attachment factor for SARS-CoV-1,  
22 demonstrating that KIM-1 mediates internalization of virus, but does not enhance virus replication <sup>19</sup>. In  
23 contrast, KIM-1-mediated uptake of SARS-CoV-2 results in virus replication after internalization of virus.  
24 Previously, we reported that, following KIM-1-mediated phagocytosis of apoptotic cell bodies by renal  
25 epithelial cells, there was subsequent degradation involving autophagy <sup>16,21</sup>. We speculate that KIM-1 can  
26 work as both an attachment factor for degradation and a receptor for SARS-CoV-2. KIM-1 may start to  
27 function as a receptor when the degradation system is highly induced due to severe infection. Specifically,

1 SARS-CoV-2 infection-stressed renal proximal tubule epithelial cells may more strongly enhance KIM-1  
2 expression thus promoting a stronger degradation system than may occur in lung epithelial cells. This is  
3 the speculated reason why SARS-CoV-2 infection in kidney cannot be detected as often when compared  
4 to infection in the lung.

5 KIM-1 is upregulated by many insults to the kidney and results in AKI. We have shown that acute  
6 upregulation of KIM-1 due to injury is protective and is likely due to an anti-inflammatory and anti-  
7 obstructive response associated with phagocytosis of apoptotic debris in the tubule <sup>31</sup>. Our findings that  
8 KIM-1 is a receptor for SARS-CoV-2 indicate that KIM-1 could interact with exfoliated and virus-infected  
9 cells in the lung and kidney. Furthermore, the KIM-1 ectodomain may bind SARS-CoV-2 in the pulmonary  
10 alveoli and kidney tubular lumen and could also act as a decoy receptor. This would be reminiscent of the  
11 use of Enfuvirtide, Maraviroc and Ibalizumab for HIV where administration of agents that will bind to the  
12 virus in the circulation will compete for tissue binding <sup>44</sup>.

13 KIM-1 facilitated endocytosis of SARS-CoV-2 virosomes in both a KIM-1- and spike protein-  
14 dependent manner. Jemielity et al. demonstrated that the phosphatidylserine binding characteristics of  
15 human KIM-1/TIM-1 mediate its activity as a SARS-CoV-1 pseudovirus receptor <sup>19</sup>. It is important to  
16 recognize, however, that the virosomes we used do not contain phosphatidylserine, so the interaction of  
17 KIM-1 with this phospholipid of the virus cannot explain the KIM-1 mediated facilitation of uptake. Our  
18 binding assay confirms that the KIM-1-mediated binding interaction is with the spike protein of SARS-CoV-  
19 2.

20 Our recently discovered KIM-1 small molecule inhibitor, TW-37, blocked KIM-1-mediated  
21 endocytosis of SARS-CoV-2 virosomes in renal epithelial cells. TW-37 was originally discovered as a bcl-  
22 2 inhibitor in cancer drug screening, and is safe for use in animals <sup>45,46</sup>. Our findings that TW-37 blocked  
23 spike protein-mediated entry of the virosome suggests a potential therapeutic role for this compound in  
24 prevention of viral internalization as an approach to anti-SARS-CoV-2 viral treatment.

25 In conclusion, KIM-1 is a receptor for SARS-CoV-2 via its interaction with the spike protein. KIM-  
26 1-dependent uptake of SARS-CoV-2 by lung and kidney cells can be inhibited by anti-KIM-1 antibodies  
27 and TW-37. This may have important implications for viral entry, initiation of virus replication, and/or

- 1 inactivation of the virus through viral degradation or decoy function in the kidney and respiratory mucosa.
- 2 Targeted treatment directed at the KIM-1-SARS-CoV-2 interaction may be both therapeutic and
- 3 prophylactic for this devastating disease that occurs secondary to infection.
- 4

## 1 **Acknowledgements**

2 This work was supported by grants from the National Institute of Health/NCATS/NIDDK UH3TR002155  
3 (J.V.B. & L.P.L.); NIDDK 2R01DK072381 (J.V.B. & L.P.L.), R37DK039773 (J.V.B.) and Postdoctoral  
4 Fellowship from Uehara Memorial Foundation (to Y.M.), the Overseas Research Fellowships from Japan  
5 Society for the Promotion of Science (to Y.M.) and the Canadian Institutes of Health Research (to G.A.D.  
6 and J.D.D.). The authors would like to thank Zi-Fu Wang for help with binding experiments and thank Bing  
7 Chen and Youngfei Cai for providing purified spike ectodomain. We thank Drs. Huihui Mou and Michael  
8 Farzan for providing ACE2-293T cells. We thank Dr. Bing Chen for providing a stable Expi293F cells  
9 expressing S.dTM.PP.

10

## 11 **Author contributions**

12 Y.M., C.F., T.I., K.S., M.M., P.A., N.N.L., K.M.P.D., R.F.P., A.W., S.G.H., M.S., and M.L.N. performed  
13 experiments, collected and analyzed data, and wrote the manuscript. R.F.P. and A.W. obtained human  
14 lung and kidney samples and helped to interpret the pathology. L.P.L supported S.G.H.'s and M.S.'s  
15 experiment. G.A.D. and J.D.D supported C.F.'s SARS-CoV-2 experiments. Y.M. and J.V.B. developed  
16 experimental strategy, supervised the project, and edited the manuscript. All authors discussed the results  
17 and implications and commented on the manuscript.

18

## 19 **Competing Interests**

20 J.V.B. and T.I. are co-inventors on KIM-1 patents assigned to Partners Healthcare. J.V.B and T.I. have filed  
21 a patent for the discovery of TW-37 as inhibitor of KIM-1 to alleviate COVID-19. J.V.B. is a consultant to Aldeyra,  
22 Angion, Sarepta and Seattle Genetics, and owns equity in Goldfinch, Innoviva, MediBeacon, DxNow,  
23 Verinano, and Autonomous Medical Devices. J.V.B.'s interests were reviewed and are managed by Brigham  
24 and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.

25

## 26 **Additional Information**

27 **Correspondence and requests for materials** should be addressed to Y.M. and J.V.B.

## 1 **Figure Legends**

### 2 **Figure 1. KIM-1 is expressed in COVID-19 patient alveolar and kidney epithelia.**

3 (a) Representative immunostaining of KIM-1, SARS-CoV-2 nucleocapsid protein and pan-cytokeratin (top  
4 two rows), immunostaining of KIM-1 and SARS-CoV-2 nucleocapsid protein (3rd row), and immunostaining  
5 of ACE2, KIM-1, pan-cytokeratin and surfactant protein (bottom 2 panels) in kidney biopsy samples from  
6 COVID-19 patients. DAPI staining marks the nuclei in this and other panels. Scale bars, 20  $\mu\text{m}$ .

7 (b) Immunostaining of KIM-1 and ACE2 in a post-mortem lung sample from COVID-19 patients. Scale bar,  
8 20  $\mu\text{m}$ .

9 (c) Patient information for three COVID-19-associated AKI kidney biopsy samples. The patients' ages were  
10 at a range of 45-60 years old.

11 (d) Immunostaining of KIM-1 and ACE2 in representative post-mortem kidney biopsy samples from four  
12 COVID-19 patients. Scale bars, 20  $\mu\text{m}$ .

13 (e) Immunostaining of KIM-1 and ACE2 post ischemia-reperfusion injury (IRI) in mouse kidneys. Scale  
14 bars, 20  $\mu\text{m}$ .

15 (f) Immunohistochemistry staining of SARS-CoV-2 nucleocapsid protein in a COVID-19-associated AKI  
16 patient. Scale bars, 50  $\mu\text{m}$  (left panel), 20  $\mu\text{m}$  (right panel).

17 (g) Immunostaining of SARS-CoV-2 nucleocapsid protein in a COVID-19 post-mortem kidney section from  
18 the patient where immunohistochemistry is shown in **Fig 1f**. Scale bar, 20  $\mu\text{m}$ .

19

### 20 **Figure 2. SARS-CoV-2 virosomes containing the spike protein with both S1 and S2 subunits are** 21 **internalized by lung epithelial cells and A549 adenocarcinoma human alveolar basal epithelial cells** 22 **in a KIM-1-dependent manner.**

23 (a) Negative-stain electron micrograph of SARS-CoV-2 virosomes displaying the spike ectodomain. The  
24 spike His-tag was bind to the nickel-nitrilotriacetic acid (Ni-NTA) lipids.

25 (b) Top: A549 cell internalization of Dil-labeled virosomes as compared to control empty liposomes with  
26 equivalent Dil (0.5 nM for each). Scale bars, 20  $\mu\text{m}$ . Bottom: Quantification of internalized Dil-positive cells  
27 by flow cytometry. \* $p=0.017$ .

1 (c) Internalization of Dil-labeled virosomes by A549 cells in the presence of control mouse IgG, anti-KIM-  
2 1 (3F4 and AKG7) or TW-37, a specific inhibitor for KIM-1, or control DMSO, immunostained with KIM-1  
3 antibody (green). Scale bars, 20  $\mu\text{m}$ .

4 (d) Quantification of internalized Dil-labeled virosomes by A549 cells as measured by flow cytometry.  
5 \* $p=0.0334$ , \*\* $p=0.0017$ .

6 (e) ACE2 immunostaining after uptake of Dil-labeled virosomes into A549 cells. Scale bars, 20  $\mu\text{m}$ .

7 (f) Internalization of Dil-labeled virosomes by mouse primary lung epithelial cells from wild-type mice or  
8 KIM-1 <sup>$\Delta$ mucin</sup> mice after pretreatment with control IgG, anti-KIM-1 IgG (AF1817) or TW-37 or control DMSO.  
9 Scale bars, 20  $\mu\text{m}$ .

10 (g) Quantification of internalized Dil-labeled virosomes by mouse primary lung epithelial cells treated as  
11 described in **Fig. 2f** and measured by ImageJ. Virosome-positive areas were normalized to the average of  
12 wild-type cells treated with DMSO and control IgG. Ten fields were analyzed in two independent  
13 experiments. \* $p<0.0001$ .

14 (h) Internalization of Dil-labeled virosomes by human alveoloids with or without TW-37. Scale bar: 100  $\mu\text{m}$ .

15

16 **Figure 3. SARS-CoV-2 virosomes and pseudovirus are internalized by LLC-PK1 renal epithelial cells**  
17 **in a KIM-1-dependent manner.**

18 (a) Internalization of Dil-labeled virosomes or control Dil-labeled empty liposomes by LLC-PK1 cells stably  
19 expressing KIM-1 or control pcDNA. Scale bars, 20  $\mu\text{m}$ .

20 (b) Internalization assay of Dil-labeled virosomes on LLC-PK1 cells stably expressing human KIM-1  
21 pretreated with TW-37 or control DMSO. Scale bars, 20  $\mu\text{m}$ .

22 (c) Z-stack analysis of KIM-1-expressing LLC-PK1 cells treated with Dil-labeled virosomes with or without  
23 TW-37 by confocal microscopy. Arrowheads indicate the internalized Dil-labeled virosomes. Scale bars:  
24 10  $\mu\text{m}$ .

25 (d) Internalization of Dil-labeled virosomes by LLC-PK1 cells stably expressing KIM-1 or control pcDNA in  
26 a microfluidic channel with constant flow (0.2  $\text{dyn}/\text{cm}^2$ ). Arrows indicate direction of flow.

27 (e) After staining with an orange-color fluorescent dye, KIM-1 expressing cells and control pcDNA cells



1 were mixed, co-cultured together, and exposed to GFP-tagged SARS-CoV-2 pseudovirus (CoV2-01,  
2 SARS-CoV-2-S(GFP)) for 12 hours. Red and Green signals were imaged 1.5 days after infection.

3 (f) Immunostaining of KIM-1 (AKG7) and ACE2 in LLC-PK1 cells stably expressing human KIM-1 or control  
4 pcDNA. Scale bars, 20  $\mu$ m.

5 (g) Western blotting of ACE2, KIM-1 (cytoplasmic domain, Ab #195) and ERK1/2 for confirmation of equal  
6 loading of lanes on using extracts of LLC-PK1 cells stably expressing human KIM-1 or control pcDNA.  
7 Asterisks indicate the bands for each protein.

8 (h) Immunostaining of KIM-1 and ACE2 on LLC-PK1 cells stably expressing human KIM-1. Arrows indicate  
9 that KIM-1 expression is located in cell surface. Scale bars, 10  $\mu$ m.

10 (i) Left: Internalization assay of Dil-labeled virosomes on LLC-PK1 cells stably expressing wild-type or  
11 mutant mouse KIM-1 (wild-type, AAND mutant of WNFD binding motif in Ig domain (amino acid residues  
12 112-115) or WFAA mutant) or control pcDNA. Scale bars: 20  $\mu$ m. Right: Quantification of internalized Dil-  
13 labeled virosomes measured by ImageJ. \* $p < 0.0001$ .

14

15 **Figure 4. SARS-CoV-2 virosomes are internalized by human kidney tubuloids in a KIM-1-dependent**  
16 **manner.**

17 (a) Left: Dil-labeled virosome and control empty liposome internalization by human renal epithelial  
18 tubuloids. Right: Immunostaining of KIM-1 (green) in Dil-labeled virosome-treated tubuloids. Scale bars,  
19 20  $\mu$ m.

20 (b) Phase contrast images of human renal epithelial tubuloids treated with SARS-CoV-2 virosomes. Scale  
21 bars, 20  $\mu$ m.

22 (c) Internalization assay of Dil-labeled virosomes by human renal epithelial tubuloids infected by  
23 adenovirus expressing GFP-KIM-1 (left two panels) and immunostaining of KIM-1 and ACE2 on human  
24 renal epithelial tubuloids infected by adenovirus expressing GFP-KIM-1 or control GFP- $\beta$ -GAL (right two  
25 panels). Scale bars, 20  $\mu$ m.

26 (d) Immunostaining of KIM-1 and ACE2 in KIM-1 infected tubuloids. Scale bar, 20  $\mu$ m.

27 (e) Internalization assay of human renal epithelial tubuloids infected with adenovirus expressing GFP-KIM-

1 1 and exposed to varying dilutions of Dil-labeled virosomes. Scale bars, 20  $\mu$ m.

2 (f) Quantification by flow cytometry of ACE2 expression of tubuloids infected with adenovirus expressing  
3 GFP-KIM-1 or control GFP- $\beta$ -GAL. \* $p$ <0.0001.

4 (g) Virosome uptake and KIM-1 immunostaining in human kidney organoids, untreated (Control) or treated  
5 with cisplatin (5  $\mu$ M for 48 hr), and subsequently exposed to Dil-labeled virosomes. Scale bar, 20  $\mu$ m.

6

7 **Figure 5. KIM-1 binds SARS-CoV-2 Spike protein *in vitro* and works as a receptor for SARS-CoV-2.**

8 (a) Flow cytometry-based binding assay between KIM-1 and SARS-CoV-2 Spike protein with or without  
9 TW-37.

10 (b) Quantitative analysis of data in **Fig. 5a**. \* $p$ =0.0029, \*\* $p$ =0.0004.

11 (c) 293 cells expressing KIM-1 without ACE2, ACE2 without KIM-1, and control pcDNA were exposed to  
12 SARS-CoV-2 and replicated virus were quantified by *in vitro* microneutralization assay. \* $p$ =0.0113,  
13 \*\* $p$ =0.0027, \*\*\* $p$ =0.0001, \*\*\*\* $p$ <0.0001.

14

1 **Methods**

2 **Human post-mortem samples and biopsy samples.** Human postmortem lung and kidney samples from  
3 COVID-19 patients and human kidney biopsy samples from COVID-19-associated AKI patients were  
4 obtained from clinically indicated pathological autopsy and kidney biopsies in Brigham and Women's  
5 Hospital in Boston, US. The protocol was approved by the Institutional Review Board of the Ethics  
6 Committee of Partners Healthcare.

7  
8 **Immunofluorescence staining of paraffin sections.** Human paraffin sections of postmortem samples or  
9 biopsy samples were deparaffinized with xylene, ethanol, 2% hydrogen peroxide in methanol to ablate  
10 peroxidase activity in a microwave oven. The sections were blocked with 3% BSA-PBS and were incubated  
11 with primary antibodies for 1 hour at room temperature. After washing with PBS, sections were incubated  
12 with secondary antibodies for 30 minutes. Vectashield (Vector Laboratories, Burlingame, CA) containing  
13 DAPI (12.5 µg/mL) was applied and the slides were cover-slipped. All images were obtained by confocal  
14 microscopy (C1 Eclipse from Nikon).

15  
16 **Immunohistochemistry staining of SARS nucleocapsid protein in paraffin sections.** Human paraffin  
17 sections of postmortem samples were deparaffinized with xylene, ethanol, 2% hydrogen peroxide in  
18 methanol to ablate peroxidase activity in a microwave oven. The sections were blocked with Avidin/Biotin  
19 Blocking Kit (Vector Laboratories, Burlingame, CA) and were incubated with primary antibody (anti-SARS  
20 nucleocapsid protein) for 1 hour at room temperature. Nucleocapsid protein was detected by using  
21 Vectastain Elite ABC kit (for mouse IgG) with DAB Substrate (Vector Laboratories, Burlingame, CA) kit for  
22 peroxidase staining. The sections were counterstained with hematoxylin and then mounted with cover slips  
23 using Permount (Sigma-Aldrich, St. Louis, MO).

24  
25 **Mouse ischemia reperfusion injury (IRI).** C57BL/6 mice were purchased from Charles River  
26 Laboratories. All mouse work was performed in accordance with the animal use protocol approved by the  
27 Institutional Animal Care and User Committee of the Harvard Medical School. Mice aged 8-12 weeks and

1 weighing 20-22 g were subjected to IRI according to procedures as described previously<sup>16,47</sup>. Briefly, both  
2 kidneys were exposed by flank incisions, and the renal pedicles were clamped for 25 min at 37°C. After  
3 surgery, 1 mL of warm saline (37°C) was injected intraperitoneally for volume supplementation. Sham  
4 operations were performed by exposing both kidneys without clamping of renal pedicles. Kidney tissue  
5 was collected at 24 hours or 48 hours post IRI.

6

7 **Cell culture experiments.** Human primary renal epithelial cells were obtained from the uninvolved parts  
8 of kidneys removed for nephrectomy on the renal cell carcinoma or other kidney cancers in Brigham and  
9 Women's Hospital in Boston, US, by modifying a previously established protocol<sup>21</sup>. The protocol was  
10 approved by the Institutional Review Board of the Ethics Committee of Partners Healthcare. Mouse primary  
11 lung epithelial cells were obtained and cultured by using the same protocol<sup>21</sup>. Briefly, human renal cortex  
12 was minced, or mouse lung was taken out after sacrificed and was minced. They were digested with  
13 collagenase (0.5 mg/mL) in DMEM/F12 50:50 media for 40 minutes. The enzyme reaction was deactivated  
14 with fetal bovine serum (FBS). After gravity sedimentation for 2 minutes, supernatant was discarded. The  
15 remaining sample was washed 2 times in media and tissues were resuspended in primary cell culture  
16 medium (DMEM/F12 with BSA, transferrin, insulin, selenium, hydrocortisone, and epidermal growth factor  
17 (EGF)). The epithelial cells were cultured for 7 to 14 days before being used for experiments.

18 Mutant mouse KIM-1 expression plasmid (WFAA or AAND in phosphatidylserine-binding motif,  
19 WFND (amino acid residues 112-115 in Ig domain)) were generated by site-directed mutagenesis as  
20 previously described<sup>16</sup>. LLC-PK1 cells stably expressing human or mouse KIM-1 were generated by  
21 transfecting LLC-PK1 cells with human or mouse KIM-1 full-length cDNA in the pcDNA vector<sup>16,21</sup>. LLC-  
22 PK1 cells stably expressing empty pcDNA were used as controls.

23

24 **Virosomes assembly and purification.** SARS-CoV-2 spike ectodomain was generated by using plasmid  
25 S.dTM.PP which was previously reported<sup>48</sup>, or purchased only for **Fig. 1b** (Biotinylated SARS-CoV-2  
26 (COVID-19) S1 protein, His,Avitag™ (MALS verified), AcroBiosystems, Newark, DE). We obtained a stable  
27 Expi293F cells expressing S.dTM.PP from Dr. Bing Chen at Boston Children's Hospital. Purified SARS-

1 CoV-2 spike ectodomain with deletion of the furin cleavage site, two proline mutations, a foldon  
2 trimerization domain and a C terminal His tag was used in the virosome assembly. Chloroform lipid stocks  
3 were mixed to accomplish the following ratio 15% 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)  
4 iminodiacetic acid) succinyl] (nickel, Ni, salt) (18:1DGS nickel-nitrilotriacetic acid (NTA) Ni)/51% 2-oleoyl-  
5 1-palmitoyl-sn-glycero-3-phosphocholine (POPC)/34% 2-oleoyl-1-palmitoyl-sn-glycero-3-glycerol (POPG).  
6 The mixture was dried under argon stream and stored in a desiccator overnight. The next day the mixture  
7 was resuspended in PBS buffer to achieve a final lipid concentration of 10 mM, the resulting milky solution  
8 was repeatedly pushed through a 0.1  $\mu\text{m}$  filter membrane using an extruder until the solution was turned  
9 clear. The resulting liposome solution was calculated to have a concentration of approximately 100 nM.  
10 Liposomes were mixed with the His-tagged Spike ectodomain to achieve a ratio of 40:1 (spike-trimer:  
11 liposome). The mixture was incubated for 30 min on 4 °C to allow the spike His-tag to bind to the Ni-NTA  
12 lipids. Free spike protein was separated from spike loaded liposomes using a Superose 6 10/300 size  
13 exclusion chromatography column.

14

15 **Internalization assay of virosomes and control empty liposomes.** Cells were seeded onto 8-well  
16 chamber slide at a density of  $1-1.5 \times 10^5$  cells/well (LLC-PK1 cells stably expressing human KIM-1 or empty  
17 pcDNA, A549 cells or mouse primary lung epithelial cells). After the cells reached confluency, the cells  
18 were treated with 10  $\mu\text{M}$  TW-37 or control DMSO for 30 minutes, or with 10  $\mu\text{M}$  TW-37 or control DMSO  
19 in DMEM/F-12 media, and 0.025 mg/mL anti-KIM-1 mouse IgG (3F4) and 0.025 mg/mL anti KIM-1 mouse  
20 IgG (AKG7), or 0.05 mg/mL control mouse IgG in DMEM/F-12 media for 1 hour as pretreatment. Then  
21 virosomes or control empty liposomes were added at a ratio of 1:10 to media, and cells were incubated for  
22 1.5 hours at 37 °C. After exposure to liposomes, the cells were washed with PBS and fixed with 4%  
23 paraformaldehyde (PFA)-PBS. Immunofluorescence staining of the cells was performed according to each  
24 experiment. For quantification of internalization from images taken by confocal microscopy, virosome-  
25 positive areas were measured by ImageJ and analyzed statistically.

26 For quantification of internalization by flow cytometry, A549 cells were seeded onto 12-well plates  
27 at a density of  $4 \times 10^5$  cells/well. After the cells become mostly confluent, the cells were treated with 10  $\mu\text{M}$

1 TW-37 or control DMSO in DMEM/F-12 media, and 0.025 mg/mL anti-KIM-1 mouse IgG (3F4) and 0.025  
2 mg/mL anti KIM-1 mouse IgG (AKG7), or 0.05 mg/mL control mouse IgG in DMEM/F-12 media for 1 hour  
3 as pretreatment. Then virosomes or control empty liposomes were added at a ratio of 1:10 to media, and  
4 cells were incubated for 1.5 hours at 37 °C. After exposure to liposomes, the cells were washed with PBS  
5 and detached with 0.25% Trypsin/0.1% EDTA, fixed with 4% paraformaldehyde/5% FBS in PBS, and then  
6 immunostained with anti-KIM-1 and anti-ACE2 antibodies. Cells were analyzed by FACS Canto II (BD  
7 Biosciences). Data were analyzed using FLOWJO (FLOWJO).

8

9 **Immunofluorescence staining of cells.** After fixation with 4% PFA-PBS, the cells were permeabilized  
10 with 0.1% Triton X-100-PBS and blocked with 3% BSA-PBS for 30 minutes. Primary antibodies were  
11 applied and the slides were incubated for 1 hour at room temperature or overnight at 4 °C. After washing  
12 with PBS, the slides were exposed to secondary antibodies and incubated for 30 minutes at room  
13 temperature. All images were obtained by confocal microscopy (C1 Eclipse from Nikon).

14

15 **Antibodies.** In immunofluorescence staining, primary antibodies against the following proteins were used:  
16 human KIM-1 (goat, 1:200, AF1750; R&D systems Inc, Minneapolis, MN); human KIM-1 (mouse, 1:1,  
17 AKG7<sup>20</sup>, developed in collaboration with BIOGEN Inc. Cambridge, MA); mouse KIM-1 (goat, 1:200,  
18 AF1817; R&D systems Inc, Minneapolis, MN); SARS Coronavirus Nucleocapsid (rabbit, 1:200, PA1-41098;  
19 Invitrogen, Thermo Fisher Scientific, Waltham, MA); ACE2 (rabbit, 1:200, ab15348; Abcam, Cambridge,  
20 MA); Prosurfactant Protein C (rabbit, 1:200, ab90716; Abcam, Cambridge, MA); pan-cytokeratin (mouse,  
21 1:200, Sigma-Aldrich, St. Louis, MO). Secondary antibodies were either FITC-, Cy3- or Cy5- conjugated  
22 (Jackson ImmunoResearch Inc., West Grove, PA). For western blotting, primary antibodies against the  
23 following proteins were used: ACE2 (1:1000, as used in immunofluorescence staining); human KIM-1  
24 cytoplasmic domain (rabbit, 1:1000, #195, developed in collaboration with BIOGEN Inc. Cambridge, MA  
25<sup>49</sup>); ERK1/2 (goat, 1:1000, Santa Cruz Biotechnology, Dallas, TX). As secondary antibodies, HRP-  
26 conjugated anti-rabbit IgG and anti-goat IgG (Dako, Denmark) were used. For inhibition of KIM-1 by  
27 antibodies, purified anti-human KIM-1 IgG (both mouse monoclonal AKG7 and 3F4, developed by our

1 group) or anti-mouse KIM-1 IgG (AF1817) were used. Control mouse IgG was purchased from Jackson  
2 ImmunoResearch Inc. (West Grove, PA).

3

4 **Western blotting.** Cells and kidneys were lysed and protein was purified as previously described <sup>11</sup>. Bands  
5 were visualized by chemiluminescence (Western Lightning, PerkinElmer, Waltham, MA).

6

7 **Human alveoloids.** A549 cells were cultured in ultra-low attachment plates with 10% FBS-DMEM. After  
8 around 8 weeks, alveoloids were used for experiments.

9

10 **Human renal tubuloids.** The manuscript on the protocol to make human renal tubuloids is in preparation.  
11 Briefly, human primary renal epithelial cells were cultured on ultra-low attachment plates with 5% FBS-  
12 RPMI. After 2-3 days incubation, Matrigel was added and media was changed to 5% FBS-Advanced RPMI  
13 containing EGF, bFGF and HGF. Media was changed once or twice a week. The tubuloids are ready for  
14 use after 2 weeks. Adenoviruses for expression of human KIM-1 or control  $\beta$ -galactosidase ( $\beta$ -GAL) were  
15 produced and stored as described previously <sup>49</sup>.

16

17 **Human kidney organoids. Human kidney organoids were derived from H9 embryonic pluripotent**  
18 **stem cells** (hESC). Organoids were generated following the methods in our previous study with  
19 modifications <sup>50</sup>. Briefly, H9 hESC were grown in mTeSR1 (Stemcell Technologies). Cells were dissociated  
20 and plated for differentiation process. Plated cells were differentiated utilizing the drugs and factors outlined  
21 in the previous study including Rock Inhibitor (Tocris), CHIR (Tocris), and FGF9 (R&D Systems) in  
22 Advanced RPMI media (Thermo Fischer) and grown to maturity in 96 well ultra-low attachment plate  
23 (Corning). The human kidney organoids were harvested for use after day 30 from the beginning of  
24 differentiation.

25

26 **In vitro binding assay.** 10  $\mu$ L of Biotinylated 2019-nCoV S1 protein, His, Avitag, 25  $\mu$ L of FluoSpheres  
27 NeutrAvidin-Labeled Microspheres, 1.0  $\mu$ m, nonfluorescent, 1% solids (Thermo Fisher Scientific, MA), and

1 250  $\mu$ L PBS were mixed and incubated for 30 minutes at room temperature on a belly dancer. The  
2 microspheres were washed by PBS, then incubated with or without 10  $\mu$ M TW-37 at room temperature for  
3 15 minutes. 10  $\mu$ L of Recombinant Human TIM-1/KIM-1/HAVCR1 Fc Chimera Protein (0.5 mg/mL, 9319-  
4 TM; R&D systems Inc, Minneapolis, MN) was added into the mixture. After incubation at room temperature  
5 for 1 hour on a belly dancer, the microspheres were washed by PBS. FITC-conjugated goat-anti-human  
6 Fc antibody was applied and the mixture was incubated at room temperature for 30 minutes. After washing  
7 with PBS, the microspheres were analyzed by FACS Canto II (BD Biosciences). Data were analyzed using  
8 FLOWJO (FLOWJO).

9

10 ***In vitro* microneutralization assay for SARS-CoV-2.** An *in vitro* microneutralization assay for SARS-  
11 CoV-2 was conducted using a previously defined protocol<sup>33</sup>. Briefly, 293 cells stably expressing KIM-1 or  
12 control pcDNA, or 293T cells stably expressing ACE2 were seeded on a 96-well plate and infected with  
13 replication-competent SARS-CoV-2 USA-WA1/2020 virus strain in Biosafety Level 3 (BSL-3) laboratory.  
14 After 24 hours, SARS-CoV-2 infection was quantified using mouse anti-SARS-CoV-2 nucleocapsid protein  
15 and anti-mouse IgG HRP antibodies and an OPD developing solution. The optical density at 490 nm was  
16 measured using a microplate reader and served as the assay readout.

17

18 **Pseudovirus binding and entry into LLC-PK1 co-cultured cells.** KIM-1-PK1 cells and control pcDNA-  
19 PK1 cells were cultured separately in 12-well plates before the co-culture. KIM-1-PK1 was stained with an  
20 orange-color fluorescent dye (CellTracker Orange CMRA, Thermofisher Scientific, MA) for 30min before  
21 detached. KIM-1-PK1 cells and pcDNA-PKA cells were single-cell dissociated with Trypsin/EDTA and  
22 mixed as 2:1 ratio in plating. At 90% confluency, the cells were transduced with coronavirus-based SARS-  
23 CoV-2 pseudovirus (CoV2-01, SARS-CoV-2-S(GFP), Virongy, VA) for 12 hours, refreshed with media, and  
24 imaged 1.5 days after transfection.

25

26 **Cell lines and reagents.** LLC-PK1 cell lines, A549 cell lines and 293 cell lines were obtained from the  
27 ATCC. FBS, DMEM, and DMEM/F-12 were from Cellgro (Manassas, VA). Cell lines stably expressing



1 pcDNA or KIM-1 were generated as described previously<sup>21</sup>. ACE2-293T cells were kindly provided by Drs.  
2 Huihui Mou and Michael Farzan<sup>51</sup>. TW-37 was purchased from Selleck Chemicals (Houston, TX). For  
3 labeling the virosomes and empty liposomes, CellTracker CM-Dil was purchased from Molecular Probes,  
4 Inc (Eugene, OR).

5

6 **Statistical methods.** Data are reported as mean  $\pm$  standard error of the mean (SEM). Number of samples  
7 assayed in each experiment is indicated in the Figure Legends. Tukey-Kramer Multiple Comparisons Test  
8 was used for multiple comparisons.  $p < 0.05$  was considered to represent a statistically significant difference.  
9 Prism 8 (GraphPad Software, LLC) was used for all the statistical analysis.

10

#### 11 **Resource Availability**

#### 12 **Lead Contact**

13 Further information and requests for resources and reagents should be directed to and will be fulfilled by  
14 the Lead Contact, Joseph V. Bonventre ([joseph\\_bonventre@hms.harvard.edu](mailto:joseph_bonventre@hms.harvard.edu)).

#### 15 **Material Availability**

16 This study did not generate new unique reagents.

#### 17 **Data and Code Availability**

18 All other data are available from the Lead Contact on reasonable request.

19

## References

- 1 [1](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it) [Naming the coronavirus disease \(COVID-19\) and the virus that causes it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it), <[https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)> (2020).
- 2 Hui, D. S. *et al.* The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* **91**, 264-266, doi:10.1016/j.ijid.2020.01.009 (2020).
- 3 *WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020*, <<https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>> (2020).
- 4 *Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)*, <<https://coronavirus.jhu.edu/map.html>> (2020).
- 5 Li, Z. *et al.* Caution on Kidney Dysfunctions of 2019-nCoV Patients. *medRxiv*, 2020.2002.2008.20021212, doi:10.1101/2020.02.08.20021212 (2020).
- 6 Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507-513, doi:10.1016/S0140-6736(20)30211-7 (2020).
- 7 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 8 Cheng, Y. *et al.* Kidney impairment is associated with in-hospital death of COVID-19 patients. *medRxiv*, 2020.2002.2018.20023242, doi:10.1101/2020.02.18.20023242 (2020).
- 9 Chen, T. *et al.* Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* **368**, m1091, doi:10.1136/bmj.m1091 (2020).
- 10 Kaplan, G. *et al.* Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. *Embo j* **15**, 4282-4296 (1996).
- 11 Ichimura, T. *et al.* Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. *The Journal of biological chemistry* **273**, 4135-4142 (1998).
- 12 Ichimura, T., Hung, C. C., Yang, S. A., Stevens, J. L. & Bonventre, J. V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. *American journal of physiology. Renal physiology* **286**, F552-563, doi:10.1152/ajprenal.00285.2002 (2004).
- 13 Vaidya, V. S. *et al.* Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. *Nat Biotechnol* **28**, 478-485, doi:10.1038/nbt.1623 (2010).
- 14 Takasu, O. *et al.* Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. *Am J Respir Crit Care Med* **187**, 509-517, doi:10.1164/rccm.201211-1983OC (2013).
- 15 Sabbisetti, V. S. *et al.* Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. *J Am Soc Nephrol* **25**, 2177-2186, doi:10.1681/ASN.2013070758 (2014).
- 16 Brooks, C. R. *et al.* KIM-1-/TIM-1-mediated phagocytosis links ATG5-/ULK1-dependent clearance of apoptotic cells to antigen presentation. *Embo j* **34**, 2441-2464, doi:10.15252/embj.201489838 (2015).
- 17 Kondratowicz, A. S. *et al.* T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebola virus and Lake Victoria Marburg virus. *Proc Natl Acad Sci U S A* **108**, 8426-8431, doi:10.1073/pnas.1019030108 (2011).
- 18 Meertens, L. *et al.* The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. *Cell Host Microbe* **12**, 544-557, doi:10.1016/j.chom.2012.08.009 (2012).
- 19 Jemielity, S. *et al.* TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. *PLoS Pathog* **9**, e1003232, doi:10.1371/journal.ppat.1003232 (2013).
- 20 Bailly, V. *et al.* Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal

- 1 regeneration. *The Journal of biological chemistry* **277**, 39739-39748, doi:10.1074/jbc.M200562200 (2002).
- 2 21 Ichimura, T. *et al.* Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic  
3 phenotype on epithelial cells. *The Journal of clinical investigation* **118**, 1657-1668, doi:10.1172/jci34487  
4 (2008).
- 5 22 Mori, Y. *et al.* KIM-1 mediates fatty acid uptake by renal tubular cells to promote progressive diabetic  
6 kidney disease. *Cell metabolism* **33**, 1042-1061 e1047, doi:10.1016/j.cmet.2021.04.004 (2021).
- 7 23 Du, L. *et al.* The spike protein of SARS-CoV--a target for vaccine and therapeutic development. *Nat Rev*  
8 *Microbiol* **7**, 226-236, doi:10.1038/nrmicro2090 (2009).
- 9 24 Krueger, D. K., Kelly, S. M., Lewicki, D. N., Ruffolo, R. & Gallagher, T. M. Variations in disparate regions  
10 of the murine coronavirus spike protein impact the initiation of membrane fusion. *J Virol* **75**, 2792-2802,  
11 doi:10.1128/jvi.75.6.2792-2802.2001 (2001).
- 12 25 Lewicki, D. N. & Gallagher, T. M. Quaternary structure of coronavirus spikes in complex with  
13 carcinoembryonic antigen-related cell adhesion molecule cellular receptors. *The Journal of biological*  
14 *chemistry* **277**, 19727-19734, doi:10.1074/jbc.M201837200 (2002).
- 15 26 Huang, Y. H. *et al.* CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. *Nature* **517**, 386-390,  
16 doi:10.1038/nature13848 (2015).
- 17 27 Thomas, L. J. *et al.* Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of  
18 Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1. *Mol Cancer Ther* **15**, 2946-2954,  
19 doi:10.1158/1535-7163.MCT-16-0393 (2016).
- 20 28 Zheng, X., Xu, K., Chen, L., Zhou, Y. & Jiang, J. Prognostic value of TIM-1 expression in human non-small-  
21 cell lung cancer. *J Transl Med* **17**, 178, doi:10.1186/s12967-019-1931-2 (2019).
- 22 29 Harcourt, J. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel  
23 Coronavirus Disease, United States. *Emerg Infect Dis* **26**, doi:10.3201/eid2606.200516 (2020).
- 24 30 Xiao, S. *et al.* Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig  
25 mucin 1 (Tim-1) mucin domain-mutant mice. *Proc Natl Acad Sci U S A* **109**, 12105-12110,  
26 doi:10.1073/pnas.1120914109 (2012).
- 27 31 Yang, L. *et al.* KIM-1-mediated phagocytosis reduces acute injury to the kidney. *The Journal of clinical*  
28 *investigation* **125**, 1620-1636, doi:10.1172/jci75417 (2015).
- 29 32 Abcam. *Anti-ACE2 antibody (ab15348)*, <<https://www.abcam.com/ace2-antibody-ab15348.html>> (2021).
- 30 33 Amanat, F. *et al.* An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.  
31 *Curr Protoc Microbiol* **58**, e108, doi:10.1002/cpmc.108 (2020).
- 32 34 Yin, W., Zhang, P. L., Macknis, J. K., Lin, F. & Bonventre, J. V. Kidney injury molecule-1 identifies  
33 antemortem injury in postmortem adult and fetal kidney. *American journal of physiology. Renal physiology*  
34 **315**, F1637-F1643, doi:10.1152/ajprenal.00060.2018 (2018).
- 35 35 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a  
36 Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278, doi:10.1016/j.cell.2020.02.052 (2020).
- 37 36 Sharma, P. *et al.* COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. *J Am Soc*  
38 *Nephrol*, doi:10.1681/ASN.2020050699 (2020).
- 39 37 Kudose, S. *et al.* Kidney Biopsy Findings in Patients with COVID-19. *J Am Soc Nephrol* **31**, 1959-1968,  
40 doi:10.1681/ASN.2020060802 (2020).
- 41 38 Farkash, E. A., Wilson, A. M. & Jentzen, J. M. Ultrastructural Evidence for Direct Renal Infection with  
42 SARS-CoV-2. *J Am Soc Nephrol* **31**, 1683-1687, doi:10.1681/ASN.2020040432 (2020).
- 43 39 Su, H. *et al.* Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in  
44 China. *Kidney international* **98**, 219-227, doi:10.1016/j.kint.2020.04.003 (2020).
- 45 40 Puelles, V. G. *et al.* Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med* **383**, 590-592,  
46 doi:10.1056/NEJMc2011400 (2020).
- 47 41 Braun, F. *et al.* SARS-CoV-2 renal tropism associates with acute kidney injury. *The Lancet*,

- 1           doi:10.1016/S0140-6736(20)31759-1 (2020).
- 2   42       Santoriello, D. *et al.* Postmortem Kidney Pathology Findings in Patients with COVID-19. *J Am Soc*  
3       *Nephrol*, doi:10.1681/ASN.2020050744 (2020).
- 4   43       Schaefer, I. M. *et al.* In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. *Mod*  
5       *Pathol*, doi:10.1038/s41379-020-0595-z (2020).
- 6   44       Henrich, T. J. & Kuritzkes, D. R. HIV-1 entry inhibitors: recent development and clinical use. *Curr Opin*  
7       *Viro***3**, 51-57, doi:10.1016/j.coviro.2012.12.002 (2013).
- 8   45       Ahn, C. H. *et al.* Antitumor effect of TW-37, a BH3 mimetic in human oral cancer. *Lab Anim Res* **35**, 27,  
9       doi:10.1186/s42826-019-0028-7 (2019).
- 10 46       Lei, S. *et al.* The preclinical analysis of TW-37 as a potential anti-colorectal cancer cell agent. *PLoS One* **12**,  
11       e0184501, doi:10.1371/journal.pone.0184501 (2017).
- 12 47       Park, K. M. *et al.* Inducible nitric-oxide synthase is an important contributor to prolonged protective effects  
13       of ischemic preconditioning in the mouse kidney. *The Journal of biological chemistry* **278**, 27256-27266,  
14       doi:10.1074/jbc.M301778200 (2003).
- 15 48       Yu, J. *et al.* DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* **369**, 806-811,  
16       doi:10.1126/science.abc6284 (2020).
- 17 49       Zhang, Z., Humphreys, B. D. & Bonventre, J. V. Shedding of the urinary biomarker kidney injury molecule-  
18       1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. *J Am Soc Nephrol* **18**, 2704-2714  
19       (2007).
- 20 50       Morizane, R. *et al.* Nephron organoids derived from human pluripotent stem cells model kidney  
21       development and injury. *Nat Biotechnol* **33**, 1193-1200, doi:10.1038/nbt.3392 (2015).
- 22 51       Mou, H. *et al.* Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-  
23       CoV-2. *bioRxiv*, doi:10.1101/2020.06.29.178459 (2020).
- 24




Figure 1




Figure 2




Figure 3




Figure 4






Figure 5